nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—Lapatinib—breast cancer	0.433	1	CrCtD
Gefitinib—CHEK2—breast cancer	0.0655	0.296	CbGaD
Gefitinib—ERBB3—breast cancer	0.0584	0.264	CbGaD
Gefitinib—EGFR—Lapatinib—breast cancer	0.0486	0.258	CbGbCtD
Gefitinib—EGFR—breast cancer	0.0262	0.118	CbGaD
Gefitinib—ABCG2—breast cancer	0.0191	0.0864	CbGaD
Gefitinib—CYP1A1—breast cancer	0.015	0.0677	CbGaD
Gefitinib—EGFR—Docetaxel—breast cancer	0.0137	0.0727	CbGbCtD
Gefitinib—CYP2D6—breast cancer	0.0112	0.0504	CbGaD
Gefitinib—CYP1A1—Toremifene—breast cancer	0.0102	0.0539	CbGbCtD
Gefitinib—CYP3A4—breast cancer	0.00957	0.0432	CbGaD
Gefitinib—ALB—breast cancer	0.00834	0.0377	CbGaD
Gefitinib—ABCB1—breast cancer	0.00796	0.036	CbGaD
Gefitinib—CYP2C9—Anastrozole—breast cancer	0.00447	0.0237	CbGbCtD
Gefitinib—CYP3A5—Lapatinib—breast cancer	0.00445	0.0236	CbGbCtD
Gefitinib—ABCG2—Tamoxifen—breast cancer	0.00402	0.0213	CbGbCtD
Gefitinib—ABCB1—Toremifene—breast cancer	0.00397	0.0211	CbGbCtD
Gefitinib—ABCG2—Mitoxantrone—breast cancer	0.00392	0.0208	CbGbCtD
Gefitinib—CYP1A1—Tamoxifen—breast cancer	0.00371	0.0197	CbGbCtD
Gefitinib—CYP2C19—Lapatinib—breast cancer	0.00359	0.019	CbGbCtD
Gefitinib—CYP3A4—Exemestane—breast cancer	0.00343	0.0182	CbGbCtD
Gefitinib—CYP2C9—Idarubicin—breast cancer	0.00339	0.018	CbGbCtD
Gefitinib—ABCG2—Paclitaxel—breast cancer	0.00313	0.0166	CbGbCtD
Gefitinib—CYP2D6—Idarubicin—breast cancer	0.0031	0.0164	CbGbCtD
Gefitinib—ABCG2—Irinotecan—breast cancer	0.00309	0.0164	CbGbCtD
Gefitinib—ABCG2—Fluorouracil—breast cancer	0.00296	0.0157	CbGbCtD
Gefitinib—ABCG2—Carboplatin—breast cancer	0.00295	0.0156	CbGbCtD
Gefitinib—CYP3A4—Letrozole—breast cancer	0.00292	0.0155	CbGbCtD
Gefitinib—ABCB1—Lapatinib—breast cancer	0.0029	0.0154	CbGbCtD
Gefitinib—CYP3A4—Anastrozole—breast cancer	0.0026	0.0138	CbGbCtD
Gefitinib—CYP3A4—Toremifene—breast cancer	0.00238	0.0126	CbGbCtD
Gefitinib—ABCG2—Docetaxel—breast cancer	0.00226	0.012	CbGbCtD
Gefitinib—CYP3A5—Tamoxifen—breast cancer	0.00223	0.0118	CbGbCtD
Gefitinib—CYP3A4—Fulvestrant—breast cancer	0.00221	0.0117	CbGbCtD
Gefitinib—ALB—Irinotecan—breast cancer	0.00213	0.0113	CbGbCtD
Gefitinib—ALB—Fluorouracil—breast cancer	0.00204	0.0108	CbGbCtD
Gefitinib—CYP3A4—Thiotepa—breast cancer	0.00197	0.0105	CbGbCtD
Gefitinib—CYP2C9—Capecitabine—breast cancer	0.00186	0.00985	CbGbCtD
Gefitinib—CYP3A4—Ixabepilone—breast cancer	0.0018	0.00956	CbGbCtD
Gefitinib—CYP2C19—Tamoxifen—breast cancer	0.0018	0.00953	CbGbCtD
Gefitinib—CYP3A4—Lapatinib—breast cancer	0.00174	0.0092	CbGbCtD
Gefitinib—CYP3A5—Paclitaxel—breast cancer	0.00173	0.0092	CbGbCtD
Gefitinib—CYP3A5—Irinotecan—breast cancer	0.00171	0.00907	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—breast cancer	0.00169	0.00895	CbGbCtD
Gefitinib—ABCG2—Methotrexate—breast cancer	0.00163	0.00867	CbGbCtD
Gefitinib—ABCB1—Vinorelbine—breast cancer	0.00161	0.00852	CbGbCtD
Gefitinib—CYP2D6—Vinorelbine—breast cancer	0.00151	0.00803	CbGbCtD
Gefitinib—CYP2C9—Tamoxifen—breast cancer	0.00149	0.00792	CbGbCtD
Gefitinib—ABCB1—Tamoxifen—breast cancer	0.00145	0.00769	CbGbCtD
Gefitinib—ABCB1—Mitoxantrone—breast cancer	0.00141	0.0075	CbGbCtD
Gefitinib—CYP2D6—Tamoxifen—breast cancer	0.00137	0.00725	CbGbCtD
Gefitinib—CYP3A4—Raloxifene—breast cancer	0.00132	0.00697	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—breast cancer	0.00125	0.00665	CbGbCtD
Gefitinib—ABCB1—Gemcitabine—breast cancer	0.00125	0.00662	CbGbCtD
Gefitinib—CYP2C9—Paclitaxel—breast cancer	0.00116	0.00617	CbGbCtD
Gefitinib—ABCB1—Paclitaxel—breast cancer	0.00113	0.00599	CbGbCtD
Gefitinib—ALB—Methotrexate—breast cancer	0.00113	0.00597	CbGbCtD
Gefitinib—ABCB1—Irinotecan—breast cancer	0.00111	0.0059	CbGbCtD
Gefitinib—CYP2C9—Fluorouracil—breast cancer	0.0011	0.00584	CbGbCtD
Gefitinib—ABCB1—Vinblastine—breast cancer	0.00099	0.00525	CbGbCtD
Gefitinib—CYP3A4—Vinorelbine—breast cancer	0.000963	0.0051	CbGbCtD
Gefitinib—CYP2D6—Vinblastine—breast cancer	0.000933	0.00495	CbGbCtD
Gefitinib—CYP3A4—Tamoxifen—breast cancer	0.000869	0.00461	CbGbCtD
Gefitinib—CYP3A4—Mitoxantrone—breast cancer	0.000847	0.00449	CbGbCtD
Gefitinib—ABCB1—Docetaxel—breast cancer	0.000816	0.00433	CbGbCtD
Gefitinib—CYP3A4—Paclitaxel—breast cancer	0.000676	0.00359	CbGbCtD
Gefitinib—CYP3A4—Irinotecan—breast cancer	0.000667	0.00354	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—breast cancer	0.000608	0.00323	CbGbCtD
Gefitinib—CYP3A4—Vinblastine—breast cancer	0.000593	0.00315	CbGbCtD
Gefitinib—ABCB1—Methotrexate—breast cancer	0.000589	0.00312	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—breast cancer	0.000573	0.00304	CbGbCtD
Gefitinib—EGFR—mammary gland—breast cancer	0.000547	0.0205	CbGeAlD
Gefitinib—CSNK1E—mammary gland—breast cancer	0.000526	0.0198	CbGeAlD
Gefitinib—ERBB3—mammary gland—breast cancer	0.000508	0.0191	CbGeAlD
Gefitinib—CYP3A4—Docetaxel—breast cancer	0.000489	0.00259	CbGbCtD
Gefitinib—MKNK2—mammary gland—breast cancer	0.000483	0.0181	CbGeAlD
Gefitinib—MKNK1—mammary gland—breast cancer	0.000477	0.0179	CbGeAlD
Gefitinib—SBK1—endometrium—breast cancer	0.000476	0.0179	CbGeAlD
Gefitinib—CSNK1E—nipple—breast cancer	0.000435	0.0163	CbGeAlD
Gefitinib—SBK1—pituitary gland—breast cancer	0.00043	0.0162	CbGeAlD
Gefitinib—IRAK4—nipple—breast cancer	0.000428	0.0161	CbGeAlD
Gefitinib—MKNK2—nipple—breast cancer	0.000399	0.015	CbGeAlD
Gefitinib—MKNK1—nipple—breast cancer	0.000394	0.0148	CbGeAlD
Gefitinib—HIPK4—female reproductive system—breast cancer	0.00039	0.0146	CbGeAlD
Gefitinib—CHEK2—pituitary gland—breast cancer	0.000375	0.0141	CbGeAlD
Gefitinib—CHEK2—adipose tissue—breast cancer	0.000373	0.014	CbGeAlD
Gefitinib—CYP3A4—Doxorubicin—breast cancer	0.000364	0.00193	CbGbCtD
Gefitinib—ERBB3—embryo—breast cancer	0.000346	0.013	CbGeAlD
Gefitinib—CHEK2—adrenal gland—breast cancer	0.000335	0.0126	CbGeAlD
Gefitinib—HIPK4—endocrine gland—breast cancer	0.00033	0.0124	CbGeAlD
Gefitinib—CHEK2—bone marrow—breast cancer	0.000324	0.0122	CbGeAlD
Gefitinib—CHEK2—female gonad—breast cancer	0.000312	0.0117	CbGeAlD
Gefitinib—EPHA6—female reproductive system—breast cancer	0.000308	0.0116	CbGeAlD
Gefitinib—MAP2K5—nipple—breast cancer	0.00029	0.0109	CbGeAlD
Gefitinib—MKNK1—Estradiol—Fulvestrant—breast cancer	0.000288	0.207	CbGdCrCtD
Gefitinib—ERBB3—epithelium—breast cancer	0.000283	0.0106	CbGeAlD
Gefitinib—MAP3K19—female reproductive system—breast cancer	0.00028	0.0105	CbGeAlD
Gefitinib—CSNK1E—skin of body—breast cancer	0.000279	0.0105	CbGeAlD
Gefitinib—ERBB3—skin of body—breast cancer	0.000269	0.0101	CbGeAlD
Gefitinib—MKNK2—epithelium—breast cancer	0.000269	0.0101	CbGeAlD
Gefitinib—CSNK1E—endometrium—breast cancer	0.000263	0.00987	CbGeAlD
Gefitinib—EPHA6—endocrine gland—breast cancer	0.000261	0.00979	CbGeAlD
Gefitinib—IRAK4—endometrium—breast cancer	0.000259	0.00971	CbGeAlD
Gefitinib—EGFR—uterus—breast cancer	0.000252	0.00946	CbGeAlD
Gefitinib—ALB—mammary gland—breast cancer	0.00025	0.00937	CbGeAlD
Gefitinib—EGFR—adipose tissue—breast cancer	0.000246	0.00925	CbGeAlD
Gefitinib—CSNK1E—uterus—breast cancer	0.000242	0.00909	CbGeAlD
Gefitinib—Lapatinib—ERBB4—breast cancer	0.000242	0.0919	CrCbGaD
Gefitinib—MKNK2—endometrium—breast cancer	0.000241	0.00905	CbGeAlD
Gefitinib—MKNK1—endometrium—breast cancer	0.000238	0.00894	CbGeAlD
Gefitinib—CSNK1E—pituitary gland—breast cancer	0.000238	0.00893	CbGeAlD
Gefitinib—CSNK1E—adipose tissue—breast cancer	0.000237	0.00889	CbGeAlD
Gefitinib—IRAK4—pituitary gland—breast cancer	0.000234	0.00879	CbGeAlD
Gefitinib—ERBB3—uterus—breast cancer	0.000234	0.00877	CbGeAlD
Gefitinib—IRAK4—adipose tissue—breast cancer	0.000233	0.00875	CbGeAlD
Gefitinib—SBK1—lymph node—breast cancer	0.000231	0.00866	CbGeAlD
Gefitinib—ERBB3—adipose tissue—breast cancer	0.000228	0.00858	CbGeAlD
Gefitinib—MKNK2—uterus—breast cancer	0.000222	0.00834	CbGeAlD
Gefitinib—EGFR—adrenal gland—breast cancer	0.000221	0.0083	CbGeAlD
Gefitinib—MKNK2—pituitary gland—breast cancer	0.000218	0.00819	CbGeAlD
Gefitinib—CSNK1E—female reproductive system—breast cancer	0.000218	0.00817	CbGeAlD
Gefitinib—MKNK2—adipose tissue—breast cancer	0.000217	0.00816	CbGeAlD
Gefitinib—IRAK1—adipose tissue—breast cancer	0.000217	0.00816	CbGeAlD
Gefitinib—MKNK1—pituitary gland—breast cancer	0.000215	0.00809	CbGeAlD
Gefitinib—MKNK1—adipose tissue—breast cancer	0.000215	0.00806	CbGeAlD
Gefitinib—CSNK1E—adrenal gland—breast cancer	0.000212	0.00798	CbGeAlD
Gefitinib—ERBB3—female reproductive system—breast cancer	0.00021	0.00789	CbGeAlD
Gefitinib—IRAK4—adrenal gland—breast cancer	0.000209	0.00785	CbGeAlD
Gefitinib—EGFR—female gonad—breast cancer	0.000206	0.00773	CbGeAlD
Gefitinib—IRAK4—bone marrow—breast cancer	0.000202	0.0076	CbGeAlD
Gefitinib—CHEK2—lymph node—breast cancer	0.000201	0.00754	CbGeAlD
Gefitinib—MKNK2—female reproductive system—breast cancer	0.0002	0.0075	CbGeAlD
Gefitinib—IRAK1—female reproductive system—breast cancer	0.0002	0.0075	CbGeAlD
Gefitinib—CSNK1E—female gonad—breast cancer	0.000198	0.00744	CbGeAlD
Gefitinib—MKNK1—female reproductive system—breast cancer	0.000197	0.00741	CbGeAlD
Gefitinib—IRAK4—female gonad—breast cancer	0.000195	0.00732	CbGeAlD
Gefitinib—MKNK2—adrenal gland—breast cancer	0.000195	0.00732	CbGeAlD
Gefitinib—IRAK1—adrenal gland—breast cancer	0.000195	0.00732	CbGeAlD
Gefitinib—MKNK1—adrenal gland—breast cancer	0.000192	0.00723	CbGeAlD
Gefitinib—ERBB3—female gonad—breast cancer	0.000191	0.00718	CbGeAlD
Gefitinib—IRAK1—bone marrow—breast cancer	0.000189	0.00708	CbGeAlD
Gefitinib—MKNK2—bone marrow—breast cancer	0.000189	0.00708	CbGeAlD
Gefitinib—MKNK1—bone marrow—breast cancer	0.000186	0.00699	CbGeAlD
Gefitinib—CSNK1E—endocrine gland—breast cancer	0.000184	0.00692	CbGeAlD
Gefitinib—MKNK2—female gonad—breast cancer	0.000182	0.00682	CbGeAlD
Gefitinib—IRAK1—female gonad—breast cancer	0.000182	0.00682	CbGeAlD
Gefitinib—STK10—uterus—breast cancer	0.000181	0.00678	CbGeAlD
Gefitinib—MKNK1—female gonad—breast cancer	0.000179	0.00674	CbGeAlD
Gefitinib—Lapatinib—ERBB2—breast cancer	0.000179	0.0678	CrCbGaD
Gefitinib—ERBB3—endocrine gland—breast cancer	0.000178	0.00667	CbGeAlD
Gefitinib—STK10—adipose tissue—breast cancer	0.000177	0.00663	CbGeAlD
Gefitinib—MAP2K5—endometrium—breast cancer	0.000175	0.00657	CbGeAlD
Gefitinib—Afatinib—ERBB4—breast cancer	0.000172	0.0651	CrCbGaD
Gefitinib—MKNK2—endocrine gland—breast cancer	0.000169	0.00635	CbGeAlD
Gefitinib—CHEK2—Docetaxel—Paclitaxel—breast cancer	0.000168	0.121	CbGdCrCtD
Gefitinib—MKNK1—endocrine gland—breast cancer	0.000167	0.00627	CbGeAlD
Gefitinib—STK10—female reproductive system—breast cancer	0.000162	0.0061	CbGeAlD
Gefitinib—STK10—adrenal gland—breast cancer	0.000158	0.00595	CbGeAlD
Gefitinib—MAP2K5—pituitary gland—breast cancer	0.000158	0.00595	CbGeAlD
Gefitinib—MAP2K5—adipose tissue—breast cancer	0.000158	0.00592	CbGeAlD
Gefitinib—CYP2C9—mammary gland—breast cancer	0.000156	0.00585	CbGeAlD
Gefitinib—STK10—bone marrow—breast cancer	0.000153	0.00576	CbGeAlD
Gefitinib—STK10—female gonad—breast cancer	0.000148	0.00555	CbGeAlD
Gefitinib—MAP2K5—female reproductive system—breast cancer	0.000145	0.00545	CbGeAlD
Gefitinib—ORM1—endometrium—breast cancer	0.000142	0.00534	CbGeAlD
Gefitinib—MAP2K5—adrenal gland—breast cancer	0.000141	0.00531	CbGeAlD
Gefitinib—STK10—endocrine gland—breast cancer	0.000137	0.00516	CbGeAlD
Gefitinib—CYP1A1—nipple—breast cancer	0.000134	0.00503	CbGeAlD
Gefitinib—EGFR—lymph node—breast cancer	0.000132	0.00497	CbGeAlD
Gefitinib—MAP2K5—female gonad—breast cancer	0.000132	0.00496	CbGeAlD
Gefitinib—CSNK1E—lymph node—breast cancer	0.000127	0.00478	CbGeAlD
Gefitinib—Afatinib—ERBB2—breast cancer	0.000127	0.0481	CrCbGaD
Gefitinib—Bosutinib—BMPR2—breast cancer	0.000127	0.0481	CrCbGaD
Gefitinib—Bosutinib—EPHB4—breast cancer	0.000127	0.0481	CrCbGaD
Gefitinib—IRAK4—lymph node—breast cancer	0.000125	0.00471	CbGeAlD
Gefitinib—ERBB3—lymph node—breast cancer	0.000123	0.00461	CbGeAlD
Gefitinib—MAP2K5—endocrine gland—breast cancer	0.000123	0.00461	CbGeAlD
Gefitinib—ORM1—female reproductive system—breast cancer	0.000118	0.00442	CbGeAlD
Gefitinib—MKNK2—lymph node—breast cancer	0.000117	0.00439	CbGeAlD
Gefitinib—IRAK1—lymph node—breast cancer	0.000117	0.00439	CbGeAlD
Gefitinib—Bosutinib—CDK2—breast cancer	0.000116	0.044	CrCbGaD
Gefitinib—MKNK1—lymph node—breast cancer	0.000115	0.00433	CbGeAlD
Gefitinib—ORM1—bone marrow—breast cancer	0.000111	0.00417	CbGeAlD
Gefitinib—CHEK2—Vindesine—Vinorelbine—breast cancer	0.000107	0.0767	CbGdCrCtD
Gefitinib—ALB—adrenal gland—breast cancer	0.000101	0.00378	CbGeAlD
Gefitinib—ORM1—endocrine gland—breast cancer	9.96e-05	0.00374	CbGeAlD
Gefitinib—Afatinib—ABL1—breast cancer	9.85e-05	0.0374	CrCbGaD
Gefitinib—STK10—lymph node—breast cancer	9.5e-05	0.00357	CbGeAlD
Gefitinib—CYP1A1—epithelium—breast cancer	9.01e-05	0.00339	CbGeAlD
Gefitinib—CYP1A1—skin of body—breast cancer	8.57e-05	0.00322	CbGeAlD
Gefitinib—CHEK2—Vindesine—Vinblastine—breast cancer	8.54e-05	0.0613	CbGdCrCtD
Gefitinib—ABCG2—endometrium—breast cancer	8.52e-05	0.0032	CbGeAlD
Gefitinib—MAP2K5—lymph node—breast cancer	8.48e-05	0.00319	CbGeAlD
Gefitinib—Lapatinib—EGFR—breast cancer	8.45e-05	0.0321	CrCbGaD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—breast cancer	8.39e-05	0.0602	CbGdCrCtD
Gefitinib—ABCG2—uterus—breast cancer	7.85e-05	0.00295	CbGeAlD
Gefitinib—ABCG2—pituitary gland—breast cancer	7.71e-05	0.00289	CbGeAlD
Gefitinib—ABCG2—adipose tissue—breast cancer	7.67e-05	0.00288	CbGeAlD
Gefitinib—Bosutinib—ERBB4—breast cancer	7.47e-05	0.0283	CrCbGaD
Gefitinib—CYP1A1—uterus—breast cancer	7.45e-05	0.0028	CbGeAlD
Gefitinib—CYP1A1—adipose tissue—breast cancer	7.29e-05	0.00274	CbGeAlD
Gefitinib—CYP3A5—adipose tissue—breast cancer	7.12e-05	0.00268	CbGeAlD
Gefitinib—CYP2C19—endocrine gland—breast cancer	7.03e-05	0.00264	CbGeAlD
Gefitinib—Erlotinib—ABL1—breast cancer	6.96e-05	0.0264	CrCbGaD
Gefitinib—ORM1—lymph node—breast cancer	6.89e-05	0.00259	CbGeAlD
Gefitinib—ABCG2—adrenal gland—breast cancer	6.88e-05	0.00259	CbGeAlD
Gefitinib—ERBB3—Vinblastine—Vinorelbine—breast cancer	6.86e-05	0.0493	CbGdCrCtD
Gefitinib—CYP1A1—female reproductive system—breast cancer	6.7e-05	0.00252	CbGeAlD
Gefitinib—ABCG2—bone marrow—breast cancer	6.66e-05	0.0025	CbGeAlD
Gefitinib—Minaprine—ACHE—breast cancer	6.65e-05	0.0253	CrCbGaD
Gefitinib—Bosutinib—CHEK2—breast cancer	6.53e-05	0.0248	CrCbGaD
Gefitinib—CYP2C9—female reproductive system—breast cancer	6.44e-05	0.00242	CbGeAlD
Gefitinib—ABCG2—female gonad—breast cancer	6.42e-05	0.00241	CbGeAlD
Gefitinib—Vandetanib—ERBB3—breast cancer	6.22e-05	0.0236	CrCbGaD
Gefitinib—CHEK2—Epirubicin—Idarubicin—breast cancer	6.12e-05	0.0439	CbGdCrCtD
Gefitinib—CHEK2—Doxorubicin—Idarubicin—breast cancer	6.12e-05	0.0439	CbGdCrCtD
Gefitinib—CYP1A1—female gonad—breast cancer	6.09e-05	0.00229	CbGeAlD
Gefitinib—ALB—lymph node—breast cancer	6.04e-05	0.00227	CbGeAlD
Gefitinib—Afatinib—EGFR—breast cancer	5.99e-05	0.0227	CrCbGaD
Gefitinib—CYP3A5—female gonad—breast cancer	5.96e-05	0.00224	CbGeAlD
Gefitinib—Bosutinib—ALK—breast cancer	5.82e-05	0.0221	CrCbGaD
Gefitinib—Bosutinib—ERBB3—breast cancer	5.82e-05	0.0221	CrCbGaD
Gefitinib—CHEK2—Vincristine—Vinorelbine—breast cancer	5.77e-05	0.0414	CbGdCrCtD
Gefitinib—ABCB1—embryo—breast cancer	5.74e-05	0.00216	CbGeAlD
Gefitinib—CYP1A1—endocrine gland—breast cancer	5.67e-05	0.00213	CbGeAlD
Gefitinib—CYP3A5—endocrine gland—breast cancer	5.54e-05	0.00208	CbGeAlD
Gefitinib—Bosutinib—CSF1R—breast cancer	5.51e-05	0.0209	CrCbGaD
Gefitinib—CSNK1E—Danazol—Fluoxymesterone—breast cancer	5.48e-05	0.0394	CbGdCrCtD
Gefitinib—CYP2C9—endocrine gland—breast cancer	5.45e-05	0.00205	CbGeAlD
Gefitinib—CHEK2—Vinorelbine—Vinblastine—breast cancer	5.39e-05	0.0387	CbGdCrCtD
Gefitinib—CYP3A4—female reproductive system—breast cancer	4.91e-05	0.00185	CbGeAlD
Gefitinib—CYP2D6—female reproductive system—breast cancer	4.84e-05	0.00182	CbGeAlD
Gefitinib—ABCB1—epithelium—breast cancer	4.68e-05	0.00176	CbGeAlD
Gefitinib—CHEK2—Vinblastine—Vinorelbine—breast cancer	4.64e-05	0.0333	CbGdCrCtD
Gefitinib—CHEK2—Vincristine—Vinblastine—breast cancer	4.61e-05	0.0331	CbGdCrCtD
Gefitinib—Vandetanib—ABL1—breast cancer	4.58e-05	0.0174	CrCbGaD
Gefitinib—Erlotinib—CYP1B1—breast cancer	4.48e-05	0.017	CrCbGaD
Gefitinib—CYP2D6—female gonad—breast cancer	4.4e-05	0.00165	CbGeAlD
Gefitinib—Afatinib—ABCG2—breast cancer	4.38e-05	0.0166	CrCbGaD
Gefitinib—Bosutinib—ABL1—breast cancer	4.29e-05	0.0163	CrCbGaD
Gefitinib—Erlotinib—EGFR—breast cancer	4.23e-05	0.0161	CrCbGaD
Gefitinib—ABCB1—endometrium—breast cancer	4.2e-05	0.00158	CbGeAlD
Gefitinib—CYP3A4—endocrine gland—breast cancer	4.16e-05	0.00156	CbGeAlD
Gefitinib—Vandetanib—SRC—breast cancer	4.15e-05	0.0158	CrCbGaD
Gefitinib—ABCG2—lymph node—breast cancer	4.13e-05	0.00155	CbGeAlD
Gefitinib—CYP2D6—endocrine gland—breast cancer	4.09e-05	0.00154	CbGeAlD
Gefitinib—CYP1A1—lymph node—breast cancer	3.92e-05	0.00147	CbGeAlD
Gefitinib—Vandetanib—KDR—breast cancer	3.9e-05	0.0148	CrCbGaD
Gefitinib—Bosutinib—SRC—breast cancer	3.88e-05	0.0147	CrCbGaD
Gefitinib—ABCB1—uterus—breast cancer	3.87e-05	0.00145	CbGeAlD
Gefitinib—Vandetanib—ABCC1—breast cancer	3.86e-05	0.0147	CrCbGaD
Gefitinib—ABCB1—pituitary gland—breast cancer	3.8e-05	0.00143	CbGeAlD
Gefitinib—ABCB1—adipose tissue—breast cancer	3.78e-05	0.00142	CbGeAlD
Gefitinib—CSNK1E—Betamethasone—Fluoxymesterone—breast cancer	3.5e-05	0.0251	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Fluoxymesterone—breast cancer	3.5e-05	0.0251	CbGdCrCtD
Gefitinib—ABCB1—female reproductive system—breast cancer	3.48e-05	0.00131	CbGeAlD
Gefitinib—ABCB1—adrenal gland—breast cancer	3.39e-05	0.00127	CbGeAlD
Gefitinib—CHEK2—Testosterone Propionate—Fluoxymesterone—breast cancer	3.38e-05	0.0242	CbGdCrCtD
Gefitinib—Vandetanib—VEGFA—breast cancer	3.3e-05	0.0125	CrCbGaD
Gefitinib—ABCB1—bone marrow—breast cancer	3.28e-05	0.00123	CbGeAlD
Gefitinib—ABCB1—female gonad—breast cancer	3.17e-05	0.00119	CbGeAlD
Gefitinib—Erlotinib—ABCG2—breast cancer	3.09e-05	0.0117	CrCbGaD
Gefitinib—Lapatinib—CYP3A4—breast cancer	3.09e-05	0.0117	CrCbGaD
Gefitinib—ABCB1—endocrine gland—breast cancer	2.94e-05	0.00111	CbGeAlD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—breast cancer	2.81e-05	0.0202	CbGdCrCtD
Gefitinib—CHEK2—Danazol—Fluoxymesterone—breast cancer	2.81e-05	0.0201	CbGdCrCtD
Gefitinib—Vandetanib—EGFR—breast cancer	2.79e-05	0.0106	CrCbGaD
Gefitinib—Bosutinib—EGFR—breast cancer	2.61e-05	0.0099	CrCbGaD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—breast cancer	2.6e-05	0.0187	CbGdCrCtD
Gefitinib—Lapatinib—ABCB1—breast cancer	2.57e-05	0.00976	CrCbGaD
Gefitinib—CHEK2—Norethindrone—Fluoxymesterone—breast cancer	2.53e-05	0.0182	CbGdCrCtD
Gefitinib—Erlotinib—CYP1A1—breast cancer	2.42e-05	0.00919	CrCbGaD
Gefitinib—Minaprine—CYP2D6—breast cancer	2.15e-05	0.00815	CrCbGaD
Gefitinib—Vandetanib—ABCG2—breast cancer	2.04e-05	0.00773	CrCbGaD
Gefitinib—ABCB1—lymph node—breast cancer	2.03e-05	0.000764	CbGeAlD
Gefitinib—Afatinib—ABCB1—breast cancer	1.82e-05	0.00692	CrCbGaD
Gefitinib—Erlotinib—CYP2D6—breast cancer	1.8e-05	0.00684	CrCbGaD
Gefitinib—Cisapride—CYP2D6—breast cancer	1.7e-05	0.00644	CrCbGaD
Gefitinib—Hypersensitivity—Irinotecan—breast cancer	1.68e-05	0.000256	CcSEcCtD
Gefitinib—Vomiting—Thiotepa—breast cancer	1.68e-05	0.000256	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—breast cancer	1.68e-05	0.000256	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—breast cancer	1.67e-05	0.000254	CcSEcCtD
Gefitinib—Infestation—Epirubicin—breast cancer	1.67e-05	0.000254	CcSEcCtD
Gefitinib—Rash—Thiotepa—breast cancer	1.67e-05	0.000254	CcSEcCtD
Gefitinib—Dermatitis—Thiotepa—breast cancer	1.66e-05	0.000254	CcSEcCtD
Gefitinib—Dyspnoea—Paclitaxel—breast cancer	1.66e-05	0.000253	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—breast cancer	1.65e-05	0.000252	CcSEcCtD
Gefitinib—Nausea—Vinorelbine—breast cancer	1.64e-05	0.00025	CcSEcCtD
Gefitinib—Asthenia—Mitoxantrone—breast cancer	1.64e-05	0.000249	CcSEcCtD
Gefitinib—Asthenia—Irinotecan—breast cancer	1.64e-05	0.000249	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	1.63e-05	0.000249	CcSEcCtD
Gefitinib—Cough—Capecitabine—breast cancer	1.63e-05	0.000249	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—breast cancer	1.63e-05	0.000248	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—breast cancer	1.62e-05	0.000247	CcSEcCtD
Gefitinib—Decreased appetite—Paclitaxel—breast cancer	1.62e-05	0.000246	CcSEcCtD
Gefitinib—Hypersensitivity—Fluorouracil—breast cancer	1.61e-05	0.000245	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—breast cancer	1.61e-05	0.000245	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—breast cancer	1.61e-05	0.000245	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Paclitaxel—breast cancer	1.61e-05	0.000245	CcSEcCtD
Gefitinib—Fatigue—Paclitaxel—breast cancer	1.6e-05	0.000244	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—breast cancer	1.6e-05	0.000244	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—breast cancer	1.6e-05	0.000244	CcSEcCtD
Gefitinib—Asthenia—Gemcitabine—breast cancer	1.59e-05	0.000243	CcSEcCtD
Gefitinib—Pain—Paclitaxel—breast cancer	1.59e-05	0.000242	CcSEcCtD
Gefitinib—Constipation—Paclitaxel—breast cancer	1.59e-05	0.000242	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—breast cancer	1.59e-05	0.000242	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	1.58e-05	0.000241	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—breast cancer	1.58e-05	0.000241	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—breast cancer	1.58e-05	0.00024	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—breast cancer	1.57e-05	0.00024	CcSEcCtD
Gefitinib—Pruritus—Gemcitabine—breast cancer	1.57e-05	0.00024	CcSEcCtD
Gefitinib—Nausea—Thiotepa—breast cancer	1.57e-05	0.000239	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—breast cancer	1.57e-05	0.000239	CcSEcCtD
Gefitinib—Infection—Docetaxel—breast cancer	1.57e-05	0.000239	CcSEcCtD
Gefitinib—Iloperidone—CYP2D6—breast cancer	1.57e-05	0.00595	CrCbGaD
Gefitinib—Weight decreased—Doxorubicin—breast cancer	1.57e-05	0.000239	CcSEcCtD
Gefitinib—Diarrhoea—Mitoxantrone—breast cancer	1.56e-05	0.000238	CcSEcCtD
Gefitinib—Diarrhoea—Irinotecan—breast cancer	1.56e-05	0.000238	CcSEcCtD
Gefitinib—Dry mouth—Capecitabine—breast cancer	1.56e-05	0.000237	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—breast cancer	1.55e-05	0.000236	CcSEcCtD
Gefitinib—Shock—Docetaxel—breast cancer	1.55e-05	0.000236	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—breast cancer	1.55e-05	0.000236	CcSEcCtD
Gefitinib—Pruritus—Fluorouracil—breast cancer	1.55e-05	0.000235	CcSEcCtD
Gefitinib—Erlotinib—CYP3A4—breast cancer	1.55e-05	0.00587	CrCbGaD
Gefitinib—Thrombocytopenia—Docetaxel—breast cancer	1.54e-05	0.000235	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—breast cancer	1.54e-05	0.000235	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—breast cancer	1.54e-05	0.000235	CcSEcCtD
Gefitinib—Skin disorder—Docetaxel—breast cancer	1.53e-05	0.000233	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—breast cancer	1.53e-05	0.000233	CcSEcCtD
Gefitinib—Gastrointestinal pain—Paclitaxel—breast cancer	1.52e-05	0.000232	CcSEcCtD
Gefitinib—Diarrhoea—Gemcitabine—breast cancer	1.52e-05	0.000232	CcSEcCtD
Gefitinib—Infection—Capecitabine—breast cancer	1.52e-05	0.000231	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—breast cancer	1.51e-05	0.00023	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—breast cancer	1.5e-05	0.000229	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—breast cancer	1.5e-05	0.000229	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—breast cancer	1.5e-05	0.000229	CcSEcCtD
Gefitinib—Shock—Capecitabine—breast cancer	1.5e-05	0.000229	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—breast cancer	1.5e-05	0.000229	CcSEcCtD
Gefitinib—Nervous system disorder—Capecitabine—breast cancer	1.5e-05	0.000228	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—breast cancer	1.5e-05	0.000228	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—breast cancer	1.5e-05	0.000228	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—breast cancer	1.5e-05	0.000228	CcSEcCtD
Gefitinib—Diarrhoea—Fluorouracil—breast cancer	1.49e-05	0.000228	CcSEcCtD
Gefitinib—Thrombocytopenia—Capecitabine—breast cancer	1.49e-05	0.000228	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—breast cancer	1.48e-05	0.000226	CcSEcCtD
Gefitinib—Skin disorder—Capecitabine—breast cancer	1.48e-05	0.000226	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—breast cancer	1.48e-05	0.000225	CcSEcCtD
Gefitinib—Urticaria—Paclitaxel—breast cancer	1.48e-05	0.000225	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—breast cancer	1.47e-05	0.000225	CcSEcCtD
Gefitinib—Hypotension—Docetaxel—breast cancer	1.47e-05	0.000224	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—breast cancer	1.47e-05	0.000224	CcSEcCtD
Gefitinib—Body temperature increased—Paclitaxel—breast cancer	1.47e-05	0.000224	CcSEcCtD
Gefitinib—Abdominal pain—Paclitaxel—breast cancer	1.47e-05	0.000224	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—breast cancer	1.47e-05	0.000224	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—breast cancer	1.46e-05	0.000222	CcSEcCtD
Gefitinib—Cisapride—CYP3A4—breast cancer	1.46e-05	0.00553	CrCbGaD
Gefitinib—Epistaxis—Doxorubicin—breast cancer	1.46e-05	0.000222	CcSEcCtD
Gefitinib—Anorexia—Capecitabine—breast cancer	1.46e-05	0.000222	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—breast cancer	1.45e-05	0.000221	CcSEcCtD
Gefitinib—Vomiting—Mitoxantrone—breast cancer	1.45e-05	0.000221	CcSEcCtD
Gefitinib—Vomiting—Irinotecan—breast cancer	1.45e-05	0.000221	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—breast cancer	1.44e-05	0.00022	CcSEcCtD
Gefitinib—Rash—Mitoxantrone—breast cancer	1.44e-05	0.000219	CcSEcCtD
Gefitinib—Rash—Irinotecan—breast cancer	1.44e-05	0.000219	CcSEcCtD
Gefitinib—Dermatitis—Irinotecan—breast cancer	1.44e-05	0.000219	CcSEcCtD
Gefitinib—Dermatitis—Mitoxantrone—breast cancer	1.44e-05	0.000219	CcSEcCtD
Gefitinib—Hypotension—Capecitabine—breast cancer	1.43e-05	0.000217	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—breast cancer	1.42e-05	0.000216	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—breast cancer	1.41e-05	0.000215	CcSEcCtD
Gefitinib—Vomiting—Gemcitabine—breast cancer	1.41e-05	0.000215	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—breast cancer	1.41e-05	0.000214	CcSEcCtD
Gefitinib—Rash—Gemcitabine—breast cancer	1.4e-05	0.000213	CcSEcCtD
Gefitinib—Dermatitis—Gemcitabine—breast cancer	1.4e-05	0.000213	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—breast cancer	1.4e-05	0.000213	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—breast cancer	1.39e-05	0.000212	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—breast cancer	1.39e-05	0.000212	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—breast cancer	1.39e-05	0.000212	CcSEcCtD
Gefitinib—Vomiting—Fluorouracil—breast cancer	1.39e-05	0.000212	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—breast cancer	1.39e-05	0.000211	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—breast cancer	1.39e-05	0.000211	CcSEcCtD
Gefitinib—Rash—Fluorouracil—breast cancer	1.38e-05	0.00021	CcSEcCtD
Gefitinib—Dermatitis—Fluorouracil—breast cancer	1.38e-05	0.00021	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—breast cancer	1.37e-05	0.000209	CcSEcCtD
Gefitinib—Hypersensitivity—Paclitaxel—breast cancer	1.37e-05	0.000209	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—breast cancer	1.37e-05	0.000208	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—breast cancer	1.36e-05	0.000208	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Docetaxel—breast cancer	1.36e-05	0.000207	CcSEcCtD
Gefitinib—Dyspnoea—Capecitabine—breast cancer	1.36e-05	0.000207	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—breast cancer	1.36e-05	0.000207	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—breast cancer	1.36e-05	0.000207	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—breast cancer	1.36e-05	0.000207	CcSEcCtD
Gefitinib—Nausea—Mitoxantrone—breast cancer	1.36e-05	0.000206	CcSEcCtD
Gefitinib—Nausea—Irinotecan—breast cancer	1.36e-05	0.000206	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—breast cancer	1.35e-05	0.000206	CcSEcCtD
Gefitinib—Constipation—Docetaxel—breast cancer	1.35e-05	0.000205	CcSEcCtD
Gefitinib—Pain—Docetaxel—breast cancer	1.35e-05	0.000205	CcSEcCtD
Gefitinib—Erlotinib—ALB—breast cancer	1.35e-05	0.00512	CrCbGaD
Gefitinib—Iloperidone—CYP3A4—breast cancer	1.34e-05	0.0051	CrCbGaD
Gefitinib—Arrhythmia—Epirubicin—breast cancer	1.34e-05	0.000204	CcSEcCtD
Gefitinib—Asthenia—Paclitaxel—breast cancer	1.33e-05	0.000203	CcSEcCtD
Gefitinib—Decreased appetite—Capecitabine—breast cancer	1.33e-05	0.000202	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—breast cancer	1.32e-05	0.000202	CcSEcCtD
Gefitinib—Nausea—Gemcitabine—breast cancer	1.32e-05	0.000201	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Capecitabine—breast cancer	1.32e-05	0.000201	CcSEcCtD
Gefitinib—Fatigue—Capecitabine—breast cancer	1.32e-05	0.000201	CcSEcCtD
Gefitinib—Pruritus—Paclitaxel—breast cancer	1.32e-05	0.000201	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—breast cancer	1.31e-05	0.0002	CcSEcCtD
Gefitinib—Constipation—Capecitabine—breast cancer	1.31e-05	0.000199	CcSEcCtD
Gefitinib—Pain—Capecitabine—breast cancer	1.31e-05	0.000199	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—breast cancer	1.3e-05	0.000199	CcSEcCtD
Gefitinib—Nausea—Fluorouracil—breast cancer	1.3e-05	0.000198	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—breast cancer	1.29e-05	0.000197	CcSEcCtD
Gefitinib—Gastrointestinal pain—Docetaxel—breast cancer	1.29e-05	0.000196	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—breast cancer	1.29e-05	0.000196	CcSEcCtD
Gefitinib—Erlotinib—ABCB1—breast cancer	1.29e-05	0.00489	CrCbGaD
Gefitinib—Cardiac disorder—Doxorubicin—breast cancer	1.29e-05	0.000196	CcSEcCtD
Gefitinib—Diarrhoea—Paclitaxel—breast cancer	1.27e-05	0.000194	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—breast cancer	1.26e-05	0.000191	CcSEcCtD
Gefitinib—Malaise—Methotrexate—breast cancer	1.26e-05	0.000191	CcSEcCtD
Gefitinib—Gastrointestinal pain—Capecitabine—breast cancer	1.25e-05	0.00019	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—breast cancer	1.25e-05	0.00019	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—breast cancer	1.25e-05	0.00019	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—breast cancer	1.25e-05	0.00019	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—breast cancer	1.24e-05	0.000189	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—breast cancer	1.22e-05	0.000186	CcSEcCtD
Gefitinib—Cough—Methotrexate—breast cancer	1.22e-05	0.000185	CcSEcCtD
Gefitinib—Urticaria—Capecitabine—breast cancer	1.21e-05	0.000185	CcSEcCtD
Gefitinib—Abdominal pain—Capecitabine—breast cancer	1.21e-05	0.000184	CcSEcCtD
Gefitinib—Body temperature increased—Capecitabine—breast cancer	1.21e-05	0.000184	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—breast cancer	1.21e-05	0.000184	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—breast cancer	1.2e-05	0.000184	CcSEcCtD
Gefitinib—Vomiting—Paclitaxel—breast cancer	1.18e-05	0.00018	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.18e-05	0.000179	CcSEcCtD
Gefitinib—Malaise—Epirubicin—breast cancer	1.18e-05	0.000179	CcSEcCtD
Gefitinib—Rash—Paclitaxel—breast cancer	1.17e-05	0.000179	CcSEcCtD
Gefitinib—Dermatitis—Paclitaxel—breast cancer	1.17e-05	0.000179	CcSEcCtD
Gefitinib—Hypersensitivity—Docetaxel—breast cancer	1.16e-05	0.000177	CcSEcCtD
Gefitinib—Cough—Epirubicin—breast cancer	1.14e-05	0.000173	CcSEcCtD
Gefitinib—Asthenia—Docetaxel—breast cancer	1.13e-05	0.000172	CcSEcCtD
Gefitinib—Infection—Methotrexate—breast cancer	1.13e-05	0.000172	CcSEcCtD
Gefitinib—Hypersensitivity—Capecitabine—breast cancer	1.12e-05	0.000171	CcSEcCtD
Gefitinib—Pruritus—Docetaxel—breast cancer	1.12e-05	0.00017	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—breast cancer	1.11e-05	0.00017	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—breast cancer	1.11e-05	0.00017	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—breast cancer	1.11e-05	0.00017	CcSEcCtD
Gefitinib—Nausea—Paclitaxel—breast cancer	1.11e-05	0.000168	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—breast cancer	1.1e-05	0.000168	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.1e-05	0.000168	CcSEcCtD
Gefitinib—Asthenia—Capecitabine—breast cancer	1.1e-05	0.000167	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—breast cancer	1.09e-05	0.000166	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—breast cancer	1.09e-05	0.000165	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—breast cancer	1.08e-05	0.000165	CcSEcCtD
Gefitinib—Pruritus—Capecitabine—breast cancer	1.08e-05	0.000165	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—breast cancer	1.08e-05	0.000164	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—breast cancer	1.06e-05	0.000162	CcSEcCtD
Gefitinib—Infection—Epirubicin—breast cancer	1.06e-05	0.000161	CcSEcCtD
Gefitinib—Cough—Doxorubicin—breast cancer	1.05e-05	0.00016	CcSEcCtD
Gefitinib—Shock—Epirubicin—breast cancer	1.05e-05	0.000159	CcSEcCtD
Gefitinib—Diarrhoea—Capecitabine—breast cancer	1.04e-05	0.000159	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—breast cancer	1.04e-05	0.000159	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—breast cancer	1.04e-05	0.000159	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—breast cancer	1.03e-05	0.000157	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.02e-05	0.000155	CcSEcCtD
Gefitinib—Vandetanib—CYP3A4—breast cancer	1.02e-05	0.00387	CrCbGaD
Gefitinib—Anorexia—Epirubicin—breast cancer	1.01e-05	0.000154	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—breast cancer	1.01e-05	0.000154	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—breast cancer	1e-05	0.000153	CcSEcCtD
Gefitinib—Vomiting—Docetaxel—breast cancer	1e-05	0.000153	CcSEcCtD
Gefitinib—Rash—Docetaxel—breast cancer	9.94e-06	0.000151	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—breast cancer	9.94e-06	0.000151	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—breast cancer	9.93e-06	0.000151	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—breast cancer	9.88e-06	0.000151	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—breast cancer	9.81e-06	0.000149	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—breast cancer	9.8e-06	0.000149	CcSEcCtD
Gefitinib—Infection—Doxorubicin—breast cancer	9.78e-06	0.000149	CcSEcCtD
Gefitinib—Pain—Methotrexate—breast cancer	9.72e-06	0.000148	CcSEcCtD
Gefitinib—Vomiting—Capecitabine—breast cancer	9.71e-06	0.000148	CcSEcCtD
Gefitinib—Shock—Doxorubicin—breast cancer	9.68e-06	0.000148	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—breast cancer	9.65e-06	0.000147	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—breast cancer	9.64e-06	0.000147	CcSEcCtD
Gefitinib—Rash—Capecitabine—breast cancer	9.63e-06	0.000147	CcSEcCtD
Gefitinib—Dermatitis—Capecitabine—breast cancer	9.62e-06	0.000147	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—breast cancer	9.56e-06	0.000146	CcSEcCtD
Gefitinib—Bosutinib—CYP3A4—breast cancer	9.53e-06	0.00362	CrCbGaD
Gefitinib—Dyspnoea—Epirubicin—breast cancer	9.48e-06	0.000144	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—breast cancer	9.38e-06	0.000143	CcSEcCtD
Gefitinib—Nausea—Docetaxel—breast cancer	9.37e-06	0.000143	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—breast cancer	9.29e-06	0.000142	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—breast cancer	9.25e-06	0.000141	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—breast cancer	9.2e-06	0.00014	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—breast cancer	9.18e-06	0.00014	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—breast cancer	9.17e-06	0.00014	CcSEcCtD
Gefitinib—Constipation—Epirubicin—breast cancer	9.1e-06	0.000139	CcSEcCtD
Gefitinib—Pain—Epirubicin—breast cancer	9.1e-06	0.000139	CcSEcCtD
Gefitinib—Nausea—Capecitabine—breast cancer	9.07e-06	0.000138	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—breast cancer	9.03e-06	0.000138	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—breast cancer	8.98e-06	0.000137	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—breast cancer	8.98e-06	0.000137	CcSEcCtD
Gefitinib—Vandetanib—ALB—breast cancer	8.88e-06	0.00337	CrCbGaD
Gefitinib—Dyspnoea—Doxorubicin—breast cancer	8.77e-06	0.000134	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—breast cancer	8.7e-06	0.000133	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—breast cancer	8.56e-06	0.00013	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—breast cancer	8.5e-06	0.000129	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—breast cancer	8.48e-06	0.000129	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—breast cancer	8.45e-06	0.000129	CcSEcCtD
Gefitinib—Pain—Doxorubicin—breast cancer	8.42e-06	0.000128	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—breast cancer	8.42e-06	0.000128	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—breast cancer	8.41e-06	0.000128	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—breast cancer	8.41e-06	0.000128	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—breast cancer	8.37e-06	0.000128	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—breast cancer	8.15e-06	0.000124	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—breast cancer	8.05e-06	0.000123	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—breast cancer	8.04e-06	0.000123	CcSEcCtD
Gefitinib—Bosutinib—ABCB1—breast cancer	7.93e-06	0.00301	CrCbGaD
Gefitinib—Hypersensitivity—Epirubicin—breast cancer	7.84e-06	0.000119	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—breast cancer	7.82e-06	0.000119	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—breast cancer	7.78e-06	0.000119	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—breast cancer	7.78e-06	0.000119	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—breast cancer	7.78e-06	0.000118	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—breast cancer	7.63e-06	0.000116	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—breast cancer	7.53e-06	0.000115	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—breast cancer	7.28e-06	0.000111	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—breast cancer	7.25e-06	0.00011	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—breast cancer	7.23e-06	0.00011	CcSEcCtD
Gefitinib—Rash—Methotrexate—breast cancer	7.17e-06	0.000109	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—breast cancer	7.16e-06	0.000109	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—breast cancer	7.06e-06	0.000108	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—breast cancer	6.96e-06	0.000106	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—breast cancer	6.76e-06	0.000103	CcSEcCtD
Gefitinib—Nausea—Methotrexate—breast cancer	6.75e-06	0.000103	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—breast cancer	6.73e-06	0.000103	CcSEcCtD
Gefitinib—Rash—Epirubicin—breast cancer	6.71e-06	0.000102	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—breast cancer	6.7e-06	0.000102	CcSEcCtD
Gefitinib—Nausea—Epirubicin—breast cancer	6.32e-06	9.63e-05	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—breast cancer	6.26e-06	9.53e-05	CcSEcCtD
Gefitinib—Rash—Doxorubicin—breast cancer	6.21e-06	9.45e-05	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—breast cancer	6.2e-06	9.45e-05	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—breast cancer	5.85e-06	8.91e-05	CcSEcCtD
Gefitinib—EGFR—Disease—SRC—breast cancer	4.05e-07	6.69e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDOA—breast cancer	4.04e-07	6.68e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK3—breast cancer	4.04e-07	6.68e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HMOX1—breast cancer	4.03e-07	6.66e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ERCC2—breast cancer	4.03e-07	6.66e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—breast cancer	4.02e-07	6.64e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ITPR1—breast cancer	4.02e-07	6.64e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SERPINE1—breast cancer	4.01e-07	6.63e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—breast cancer	3.99e-07	6.59e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—breast cancer	3.97e-07	6.57e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—breast cancer	3.96e-07	6.55e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CB—breast cancer	3.95e-07	6.53e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOA3—breast cancer	3.92e-07	6.48e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—breast cancer	3.91e-07	6.47e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK3—breast cancer	3.91e-07	6.46e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—breast cancer	3.9e-07	6.45e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A2—breast cancer	3.9e-07	6.44e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—breast cancer	3.89e-07	6.43e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—breast cancer	3.89e-07	6.43e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—breast cancer	3.87e-07	6.4e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.87e-07	6.4e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—COMT—breast cancer	3.87e-07	6.39e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—breast cancer	3.85e-07	6.36e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—breast cancer	3.84e-07	6.36e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NCOR1—breast cancer	3.84e-07	6.36e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PLA2G4A—breast cancer	3.84e-07	6.36e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—COMT—breast cancer	3.83e-07	6.34e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—breast cancer	3.83e-07	6.33e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CAV1—breast cancer	3.83e-07	6.33e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCG2—breast cancer	3.82e-07	6.31e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTR—breast cancer	3.82e-07	6.31e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CPT1A—breast cancer	3.82e-07	6.31e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—breast cancer	3.82e-07	6.31e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—breast cancer	3.8e-07	6.28e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—breast cancer	3.8e-07	6.28e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMOX1—breast cancer	3.8e-07	6.27e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—breast cancer	3.79e-07	6.26e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ITPR1—breast cancer	3.79e-07	6.26e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—breast cancer	3.79e-07	6.26e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMOX1—breast cancer	3.76e-07	6.22e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ITPR1—breast cancer	3.75e-07	6.21e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—breast cancer	3.75e-07	6.2e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PLA2G4A—breast cancer	3.75e-07	6.2e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NCOR1—breast cancer	3.75e-07	6.2e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—breast cancer	3.75e-07	6.19e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HPGDS—breast cancer	3.74e-07	6.19e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK3—breast cancer	3.73e-07	6.16e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HBA1—breast cancer	3.72e-07	6.15e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—breast cancer	3.72e-07	6.15e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—breast cancer	3.72e-07	6.14e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CG—breast cancer	3.69e-07	6.1e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—breast cancer	3.68e-07	6.09e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—breast cancer	3.66e-07	6.06e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.66e-07	6.05e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—breast cancer	3.65e-07	6.03e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1A1—breast cancer	3.64e-07	6.02e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—breast cancer	3.64e-07	6.02e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MDM2—breast cancer	3.64e-07	6.01e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—breast cancer	3.63e-07	6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ACHE—breast cancer	3.63e-07	6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—breast cancer	3.63e-07	6e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—breast cancer	3.63e-07	6e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RAF1—breast cancer	3.62e-07	5.99e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—breast cancer	3.62e-07	5.98e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ERCC2—breast cancer	3.61e-07	5.98e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—breast cancer	3.61e-07	5.97e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RELA—breast cancer	3.61e-07	5.96e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—breast cancer	3.59e-07	5.94e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—breast cancer	3.58e-07	5.92e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—breast cancer	3.58e-07	5.92e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—breast cancer	3.58e-07	5.91e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—breast cancer	3.56e-07	5.88e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1A1—breast cancer	3.56e-07	5.88e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—breast cancer	3.55e-07	5.86e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—breast cancer	3.54e-07	5.86e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MTOR—breast cancer	3.54e-07	5.85e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CB—breast cancer	3.54e-07	5.85e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—breast cancer	3.54e-07	5.85e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PLA2G4A—breast cancer	3.54e-07	5.85e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NCOR1—breast cancer	3.54e-07	5.85e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ERCC2—breast cancer	3.53e-07	5.83e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—breast cancer	3.51e-07	5.8e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PLA2G4A—breast cancer	3.51e-07	5.79e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NCOR1—breast cancer	3.51e-07	5.79e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—breast cancer	3.51e-07	5.79e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAV1—breast cancer	3.49e-07	5.77e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CG—breast cancer	3.49e-07	5.77e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP17A1—breast cancer	3.44e-07	5.68e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—breast cancer	3.43e-07	5.67e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—breast cancer	3.41e-07	5.64e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO1—breast cancer	3.4e-07	5.62e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS1—breast cancer	3.4e-07	5.62e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—breast cancer	3.4e-07	5.62e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—breast cancer	3.4e-07	5.62e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—breast cancer	3.39e-07	5.6e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—breast cancer	3.39e-07	5.6e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—breast cancer	3.38e-07	5.58e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—breast cancer	3.36e-07	5.55e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1A1—breast cancer	3.35e-07	5.54e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—breast cancer	3.35e-07	5.54e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.34e-07	5.51e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2D6—breast cancer	3.34e-07	5.51e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—breast cancer	3.34e-07	5.51e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ERCC2—breast cancer	3.32e-07	5.5e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1A1—breast cancer	3.32e-07	5.49e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1B—breast cancer	3.32e-07	5.49e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—breast cancer	3.32e-07	5.48e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ERCC2—breast cancer	3.3e-07	5.45e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—breast cancer	3.28e-07	5.43e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOA2—breast cancer	3.27e-07	5.41e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—breast cancer	3.25e-07	5.38e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—breast cancer	3.25e-07	5.37e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CD—breast cancer	3.25e-07	5.37e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—breast cancer	3.23e-07	5.34e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—breast cancer	3.22e-07	5.33e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—breast cancer	3.2e-07	5.3e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CG—breast cancer	3.18e-07	5.26e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—FASN—breast cancer	3.18e-07	5.25e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—breast cancer	3.17e-07	5.23e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—breast cancer	3.16e-07	5.23e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—BCHE—breast cancer	3.16e-07	5.23e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JUN—breast cancer	3.16e-07	5.22e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—breast cancer	3.14e-07	5.18e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAV1—breast cancer	3.13e-07	5.18e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—breast cancer	3.13e-07	5.17e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC5A5—breast cancer	3.12e-07	5.16e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—breast cancer	3.12e-07	5.16e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—breast cancer	3.1e-07	5.12e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—breast cancer	3.09e-07	5.1e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—breast cancer	3.08e-07	5.09e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—breast cancer	3.07e-07	5.08e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CD—breast cancer	3.07e-07	5.07e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—breast cancer	3.07e-07	5.07e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—breast cancer	3.06e-07	5.06e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAV1—breast cancer	3.06e-07	5.06e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—breast cancer	3.06e-07	5.05e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—breast cancer	3.03e-07	5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NQO1—breast cancer	3.02e-07	4.99e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A1—breast cancer	3.02e-07	4.99e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.99e-07	4.95e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—breast cancer	2.99e-07	4.95e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK8—breast cancer	2.99e-07	4.94e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—breast cancer	2.98e-07	4.93e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—breast cancer	2.98e-07	4.93e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—breast cancer	2.95e-07	4.88e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—breast cancer	2.9e-07	4.79e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1B1—breast cancer	2.89e-07	4.78e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAV1—breast cancer	2.88e-07	4.77e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAV1—breast cancer	2.86e-07	4.72e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—breast cancer	2.86e-07	4.72e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CG—breast cancer	2.85e-07	4.72e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—breast cancer	2.85e-07	4.71e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.84e-07	4.69e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—breast cancer	2.83e-07	4.69e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CB—breast cancer	2.83e-07	4.68e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—breast cancer	2.8e-07	4.63e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CD—breast cancer	2.8e-07	4.62e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CG—breast cancer	2.79e-07	4.61e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—breast cancer	2.76e-07	4.56e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOA1—breast cancer	2.76e-07	4.56e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—breast cancer	2.73e-07	4.52e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.73e-07	4.51e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—breast cancer	2.73e-07	4.51e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—breast cancer	2.72e-07	4.5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP19A1—breast cancer	2.72e-07	4.49e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—STK11—breast cancer	2.72e-07	4.49e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CB—breast cancer	2.67e-07	4.42e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—breast cancer	2.65e-07	4.38e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—breast cancer	2.64e-07	4.36e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—breast cancer	2.63e-07	4.35e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CG—breast cancer	2.63e-07	4.34e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK3—breast cancer	2.61e-07	4.32e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CG—breast cancer	2.6e-07	4.3e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—breast cancer	2.54e-07	4.2e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—breast cancer	2.53e-07	4.19e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—COMT—breast cancer	2.53e-07	4.18e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—breast cancer	2.52e-07	4.16e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—breast cancer	2.52e-07	4.16e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CD—breast cancer	2.51e-07	4.15e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMOX1—breast cancer	2.48e-07	4.1e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—breast cancer	2.48e-07	4.1e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ITPR1—breast cancer	2.48e-07	4.09e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CD—breast cancer	2.45e-07	4.05e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—breast cancer	2.45e-07	4.04e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CB—breast cancer	2.44e-07	4.03e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—breast cancer	2.42e-07	4e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—breast cancer	2.41e-07	3.99e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—breast cancer	2.41e-07	3.98e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—breast cancer	2.38e-07	3.94e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—breast cancer	2.37e-07	3.92e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—breast cancer	2.35e-07	3.88e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—breast cancer	2.34e-07	3.87e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—breast cancer	2.31e-07	3.82e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOR1—breast cancer	2.31e-07	3.82e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—breast cancer	2.31e-07	3.82e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.31e-07	3.82e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—breast cancer	2.31e-07	3.82e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CD—breast cancer	2.31e-07	3.82e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CD—breast cancer	2.29e-07	3.78e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—breast cancer	2.28e-07	3.77e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—breast cancer	2.26e-07	3.73e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—breast cancer	2.21e-07	3.66e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1A1—breast cancer	2.19e-07	3.62e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CB—breast cancer	2.19e-07	3.62e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—breast cancer	2.18e-07	3.6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ERCC2—breast cancer	2.17e-07	3.59e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—breast cancer	2.17e-07	3.58e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—breast cancer	2.16e-07	3.57e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—breast cancer	2.16e-07	3.56e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CB—breast cancer	2.14e-07	3.53e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—breast cancer	2.12e-07	3.5e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—breast cancer	2.11e-07	3.48e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—breast cancer	2.09e-07	3.45e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—breast cancer	2.04e-07	3.38e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CB—breast cancer	2.01e-07	3.33e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—breast cancer	2e-07	3.3e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CB—breast cancer	1.99e-07	3.3e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—breast cancer	1.99e-07	3.3e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—breast cancer	1.98e-07	3.27e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—breast cancer	1.97e-07	3.25e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—breast cancer	1.91e-07	3.16e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—breast cancer	1.89e-07	3.12e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAV1—breast cancer	1.88e-07	3.12e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—breast cancer	1.85e-07	3.05e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—breast cancer	1.76e-07	2.91e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—breast cancer	1.74e-07	2.87e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—breast cancer	1.72e-07	2.85e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—breast cancer	1.72e-07	2.85e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CG—breast cancer	1.72e-07	2.84e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—breast cancer	1.63e-07	2.69e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CD—breast cancer	1.51e-07	2.49e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—breast cancer	1.49e-07	2.46e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—breast cancer	1.49e-07	2.46e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—breast cancer	1.43e-07	2.36e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—breast cancer	1.41e-07	2.33e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—breast cancer	1.33e-07	2.2e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—breast cancer	1.33e-07	2.2e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CB—breast cancer	1.32e-07	2.17e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—breast cancer	1.3e-07	2.15e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—breast cancer	1.3e-07	2.15e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—breast cancer	1.23e-07	2.03e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—breast cancer	1.22e-07	2.01e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—breast cancer	1.21e-07	2.01e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—breast cancer	1.14e-07	1.88e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—breast cancer	1.09e-07	1.8e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—breast cancer	1.06e-07	1.76e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—breast cancer	1e-07	1.66e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—breast cancer	9.93e-08	1.64e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—breast cancer	8.02e-08	1.33e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—breast cancer	6.55e-08	1.08e-06	CbGpPWpGaD
